Answers are grounded in this paper and cite their sources.
The complex nature of intravenous (IV) iron formulations makes manufacturing and characterising similars challenging. This study examined whether simple in vitro tests can distinguish the high-dose IV iron formulation, Monofer® (ferric derisomaltose [FDI]), from the first intended copies of FDI, Rapifer® (FDI intended similar A [FDIIS-A]) and Tosiron® (FDI intended similar B [FDIIS-B]), approved in India and Pakistan, respectively. Neither intended similar is available in Europe or the United States.
No takes yet. Share an insight, caveat, or question.
Langguth et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: